Abstract
Thirty B-cell chronic lymphocytic leukemia patients were treated with fludarabine–cyclophosphamide–rituximab (FCR) and immune cell counts (natural killer (NK) cells, CD4, CD8, Tγδ and monocytes) were monitored from the end of treatment (EOT) up to 36 months (M36). Moreover, nonleukemic peripheral blood lymphocyte cytotoxicity (PBL/CTC) as well as rituximab (RTX)-dependent PBL/CTC was also measured at the initiation of therapy, EOT and M12. These parameters were correlated with post-FCR monitoring of the minimal residual disease (MRD) level in blood using a four-color flow cytometry technique. FCR induced a profound and sustained depletion of all T-cell populations, Tγδ being the most affected, whereas NK cells were relatively preserved. Both basal and interleukin-2-stimulated nonleukemic PBL/CTC against MEC-2, a CLL cell line, increased during the post-FCR period. There was no correlation between immune recovery parameters and MRD progression profile, except that patients with high post-FCR CD4+ counts experienced rapid MRD progression. MRD at M12 predicts clinical relapse. The limited data show RTX-mediated LBL/CTC activity against autologous B-cell cells in individuals with <1% residual disease at M12, opening avenues for immunomodulation post-FCR with anti-CD20 antibodies. To conclude, our study suggests that MRD increase at M12 precedes disease evolution post-FCR, and should be assessed as a surrogate marker for proactive management of CLL relapse.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Tam CS, O’Brien S, Wierda W, Kantarjian H, Wen S, Do KA et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975–980.
Hallek M, Fingerle-Rowson G, Fink A, Busch R, Mayer J, Hensel M et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improve response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leulemia (CLL). Blood 2008; 112 abstract no. 325.
Milligan DW, Kochethu G, Dearden C, Matutes E, MacConkey C, Catovski D . High incidence of myelodysplasia and secondary leukaemia in the UK medical research council pilot of autografting in chronic lymphocytic leukaemia. Br J Haematol 2006; 133: 173–175.
Cheson BD, Vena DA, Barrett J, Freidin B . Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukaemia. J Clin Oncol 1999; 17: 2454–2460.
Tam CS, Seymour JF, Miles Prince H, Kenealy M, Wolf M, Januszewicz EH et al. Treatment-related myelodysplasia following fludarabine combination therapy. Haematologica 2006; 91: 1546–1550.
Ravandi F, O’Brien S . Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother 2006; 55: 197–209.
Burton JD, Weitz CH, Kay NE . Malignant chronic lymphocytic leukemia B cells elaborate soluble factors that down-regulate T cell and NK function. Am J Hematol 1989; 30: 61–67.
Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia 2008; 22: 998–1006.
Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood 2009; 113: 4875–4884.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446–5456.
Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21: 956–964.
Rawstron AC, de Tute R, Jack AS, Hillmen P . Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens. Leukemia 2006; 20: 2102–2110.
Keating MJ, O’Brien S, Lerner S, Koller C, Beran M, Robertson LE et al. Long-term follow-up of patients with chronic lymphocytic leukaemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165–1171.
Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106: 2018–2025.
Lundin J, Porwit-MacDonald A, Rossmann ED, Karlsson C, Edman P, Rezvany MR et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004; 18: 484–490.
Beum PV, Lindorfer MA, Taylor RP . Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol 2008; 181: 2916–2924.
Moreno C, Villamor N, Colomer D, Esteve J, Giné E, Muntañola A et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006; 107: 4563–4569.
Ritgen M, Böttcher S, Stilgenbauer S, Bunjes D, Schubert J, Cohen S et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia 2008; 22: 1377–1386.
Oelschlaegel U, Bornhäuser M, Kiani A, Platzbecker U, Röllig C, Wermke M et al. Flow cytometric detection of minimal residual disease one year post allogeneic stem cell transplantation predicts outcome in patients with B-CLL. Blood 2009; 114 abstract no. 202.
Egle A, Weiss L, Gassner F, Russ G, Pleyer L, Gunsilius E et al. Minimal residual disease (MRD) and T/NK cell dynamics during Fludarabine, Cyclophosphamide plus Rituximab (FCR) followed by Fludarabine plus Rituximab (FR) and remission maintenance therapy with Rituximab in previously untreated B-chronic lymphocytic leukemia (B-CLL): risk factor stratification in the Chairos study. Blood 2008; 112 abstract no. 3175.
Ghia P, Chiorazzi N, Stamatopoulos K . Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med 2008; 264: 549–562.
Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, Borleri G et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003; 88: 1002–1012.
Moga E, Alvarez E, Cantó E, Vidal S, Rodríguez-Sánchez JL, Sierra J et al. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp Hematol 2008; 36: 69–77.
Gowda A, Roda J, Hussain SR, Ramanunni A, Joshi T, Schmidt S et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood 2008; 111: 4723–4730.
Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008; 14: 4650–4657.
Acknowledgements
We are grateful to the patients who participated in the study and their referring physicians. We also thank Pr C Récher for a critical reading of the paper. This work was supported by grants from INSERM and Association Laurette Fugain (ALF/No 07-05). We thank F Hoffmann-La Roche Ltd for providing rituximab used in our experiments. EG is the recipient of a grant from Ministère délégué à l’Enseignement supérieur et à la Recherche.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ysebaert, L., Gross, E., Kühlein, E. et al. Immune recovery after fludarabine–cyclophosphamide–rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy. Leukemia 24, 1310–1316 (2010). https://doi.org/10.1038/leu.2010.89
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.89
Keywords
This article is cited by
-
Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia
BMC Cancer (2019)
-
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia
Journal of Hematology & Oncology (2017)